ALX Stock Recent News

- A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the therapeutic window -First-in-human trial of ALX2004 builds upon body of positive preclinical data demonstrating dose dependent anti-tumor activity and favorable safety profile -Initial safety data anticipated in first half 2026 SOUTH SAN FRANCISCO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the"Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that the first patient has been dosed in the Company's Phase 1 clinical trial for ALX2004, a potential best- and first-in-class, epidermal growth factor receptor (EGFR) ADC that is being studied for the treatment of EGFR-expressing solid tumors.

– Data from ASPEN-06 trial highlights CD47 expression as a key predictive biomarker of greater response to evorpacept in HER2+ Gastric Cancer; updated data to be presented at a medical conference in Q4 2025

ACIU, ABEV and ALX have been added to the Zacks Rank #5 (Strong Sell) List on August 6, 2025.

Publicly-listed US equity real estate investment trusts closed July at a median 20.3% discount to their consensus net asset value (NAV) per share estimates. The hotel REIT sector once again traded at the steepest median discount to NAV, at 35.6%. At 20.0%, the healthcare REIT sector traded at the largest premium to NAV at July-end, while the two datacenter REITs closed the recent month at a median 6.2% premium to NAV.

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced plans to report its second quarter 2025 financial results and a business update on Tuesday, August 12th, 2025, after market close.

Alexander's (ALX) came out with quarterly funds from operations (FFO) of $2.88 per share, missing the Zacks Consensus Estimate of $3.08 per share. This compares to FFO of $3.31 per share a year ago.

PARAMUS, N.J., Aug. 04, 2025 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (New York Stock Exchange: ALX) filed its Form 10-Q for the quarter ended June 30, 2025 today and reported:

PARAMUS, N.J., July 30, 2025 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that its Board of Directors has declared a regular quarterly dividend of $4.50 per share payable on August 29, 2025 to stockholders of record on August 11, 2025.

PARAMUS, N.J., July 22, 2025 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that it will file its quarterly report on Form 10-Q for the quarter ended June 30, 2025 with the U.S. Securities and Exchange Commission and issue its second quarter earnings release on Monday, August 4, 2025, before the New York Stock Exchange opens.

“Programmer.”